doi	title	authors	title_name	year	downloads	visitors	countries
10.1634/theoncologist.2014-0465	Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor	Y. Zhao, A. A. Adjei	Oncologist	2015	35	34	20
10.1634/theoncologist.2014-0443	The Role of CDK4/6 Inhibition in Breast Cancer	C. G. Murphy, M. N. Dickler	Oncologist	2015	32	29	9
10.1634/theoncologist.2014-0422	The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment	G. K. Pennock, L. Q. M. Chow	Oncologist	2015	30	27	12
10.1634/theoncologist.2014-0378	Prospective Comprehensive Genomic Profiling of Advanced Gastric Carcinoma Cases Reveals Frequent Clinically Relevant Genomic Alterations and New Routes for Targeted Therapies	S. M. Ali, E. M. Sanford, S. J. Klempner, D. A. Rubinson, K. Wang, N. A. Palma, J. Chmielecki, R. Yelensky, G. A. Palmer, D. Morosini, D. Lipson, D. V. Catenacci, F. Braiteh, R. Erlich, P. J. Stephens, J. S. Ross, S.-H. I. Ou, V. A. Miller	Oncologist	2015	26	18	7
10.1634/theoncologist.2014-0389	Fluorescence In Situ Hybridization, Immunohistochemistry, and Next-Generation Sequencing for Detection of EML4-ALK Rearrangement in Lung Cancer	M. Pekar-Zlotin, F. R. Hirsch, L. Soussan-Gutman, M. Ilouze, A. Dvir, T. Boyle, M. Wynes, V. A. Miller, D. Lipson, G. A. Palmer, S. M. Ali, S. Dekel, R. Brenner, P. A. Bunn, N. Peled	Oncologist	2015	15	15	9
10.1634/theoncologist.2014-0475	Long Noncoding RNA in Digestive Tract Cancers: Function, Mechanism, and Potential Biomarker	S. Zeng, Y.-F. Xiao, B. Tang, C.-J. Hu, R. Xie, S.-M. Yang, B.-S. Li	Oncologist	2015	13	13	2
10.1634/theoncologist.2014-0266	Diagnostic Value of Plasma and Urinary 2-Hydroxyglutarate to Identify Patients With Isocitrate Dehydrogenase-Mutated Glioma	G. Lombardi, G. Corona, L. Bellu, A. D. Puppa, A. Pambuku, P. Fiduccia, R. Bertorelle, M. P. Gardiman, D. D'Avella, G. Toffoli, V. Zagonel	Oncologist	2015	18	12	3
10.1634/theoncologist.2015-0109	Chemoimmunotherapy for Mucosa-Associated Lymphoid Tissue-Type Lymphoma: A Review of the Literature	B. Kiesewetter, A. J. M. Ferreri, M. Raderer	Oncologist	2015	12	11	7
10.1634/theoncologist.2014-0115	Evaluation and Management of the Pediatric Thyroid Nodule	J. T. Guille, A. Opoku-Boateng, S. L. Thibeault, H. Chen	Oncologist	2014	9	9	8
10.1634/theoncologist.2014-0229	Aprepitant and Fosaprepitant: A 10-Year Review of Efficacy and Safety	M. Aapro, A. Carides, B. L. Rapoport, H.-J. Schmoll, L. Zhang, D. Warr	Oncologist	2015	10	9	9
10.1634/theoncologist.2014-0234	Oncogenic Alterations in ERBB2/HER2 Represent Potential Therapeutic Targets Across Tumors From Diverse Anatomic Sites of Origin	J. Chmielecki, J. S. Ross, K. Wang, G. M. Frampton, G. A. Palmer, S. M. Ali, N. Palma, D. Morosini, V. A. Miller, R. Yelensky, D. Lipson, P. J. Stephens	Oncologist	2014	10	9	3
10.1634/theoncologist.2015-0067	Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?	A. Nazha, M. A. Sekeres, S. D. Gore, A. M. Zeidan	Oncologist	2015	9	9	6
10.1634/theoncologist.2014-0328	Systematic Literature Review and Network Meta-Analysis Comparing Bone-Targeted Agents for the Prevention of Skeletal-Related Events in Cancer Patients With Bone Metastasis	Z. Wang, D. Qiao, Y. Lu, D. Curtis, X. Wen, Y. Yao, H. Zhao	Oncologist	2015	9	8	3
10.1634/theoncologist.2014-0437	A Time-Trend Economic Analysis of Cancer Drug Trials	S. Cressman, G. P. Browman, J. S. Hoch, L. Kovacic, S. J. Peacock	Oncologist	2015	8	8	7
10.1634/theoncologist.2015-0086	The Anticipated Next Season of EGFR Inhibitors	L. V. Sequist	Oncologist	2015	7	7	3
10.1634/theoncologist.2014-0107	Breast Cancer With Brain Metastases: Clinicopathologic Features, Survival, and Paired Biomarker Analysis	Q. Shen, A. A. Sahin, K. R. Hess, D. Suki, K. D. Aldape, R. Sawaya, N. K. Ibrahim	Oncologist	2015	6	6	6
10.1634/theoncologist.2014-0182	Novel Approaches in Anaplastic Thyroid Cancer Therapy	K.-T. Hsu, X.-M. Yu, A. W. Audhya, J. C. Jaume, R. V. Lloyd, S. Miyamoto, T. A. Prolla, H. Chen	Oncologist	2014	6	6	2
10.1634/theoncologist.2014-0471	Key Issues in the Clinical Management of Gastrointestinal Stromal Tumors: An Expert Discussion	R. G. Maki, J.-Y. Blay, G. D. Demetri, J. A. Fletcher, H. Joensuu, J. Martin-Broto, T. Nishida, P. Reichardt, P. Schoffski, J. C. Trent	Oncologist	2015	6	6	4
10.1634/theoncologist.2015-0136	Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer	B. Halmos, N. A. Pennell, P. Fu, S. Saad, S. Gadgeel, G. A. Otterson, T. Mekhail, M. Snell, J. P. Kuebler, N. Sharma, A. Dowlati	Oncologist	2015	6	6	4
10.1634/theoncologist.2013-0352	New Routes to Targeted Therapy of Intrahepatic Cholangiocarcinomas Revealed by Next-Generation Sequencing	J. S. Ross, K. Wang, L. Gay, R. Al-Rohil, J. V. Rand, D. M. Jones, H. J. Lee, C. E. Sheehan, G. A. Otto, G. Palmer, R. Yelensky, D. Lipson, D. Morosini, M. Hawryluk, D. V. T. Catenacci, V. A. Miller, C. Churi, S. Ali, P. J. Stephens	Oncologist	2014	5	5	2
10.1634/theoncologist.2014-0012	A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases	J. J. Harding, F. Catalanotti, R. R. Munhoz, D. T. Cheng, A. Yaqubie, N. Kelly, G. C. McDermott, R. Kersellius, T. Merghoub, M. E. Lacouture, R. D. Carvajal, K. S. Panageas, M. F. Berger, N. Rosen, D. B. Solit, P. B. Chapman	Oncologist	2015	5	5	5
10.1634/theoncologist.2014-0032	Targeted Therapies in Metastatic Colorectal Cancer: A Systematic Review and Assessment of Currently Available Data	M. M. Kirstein, A. Lange, A. Prenzler, M. P. Manns, S. Kubicka, A. Vogel	Oncologist	2014	5	5	4
10.1634/theoncologist.2014-0037	Real-World Study of Everolimus in Advanced Progressive Neuroendocrine Tumors	F. Panzuto, M. Rinzivillo, N. Fazio, F. de Braud, G. Luppi, M. C. Zatelli, F. Lugli, P. Tomassetti, F. Riccardi, C. Nuzzo, M. P. Brizzi, A. Faggiano, A. Zaniboni, E. Nobili, D. Pastorelli, S. Cascinu, M. Merlano, S. Chiara, L. Antonuzzo, C. Funaioli, F. Spada, S. Pusceddu, A. Fontana, M. R. Ambrosio, A. Cassano, D. Campana, G. Carteni, M. Appetecchia, A. Berruti, A. Colao, M. Falconi, G. Delle Fave	Oncologist	2014	5	5	4
10.1634/theoncologist.2014-0219	The Hand-Foot Skin Reaction and Quality of Life Questionnaire: An Assessment Tool for Oncology	R. T. Anderson, K. N. Keating, H. A. Doll, F. Camacho	Oncologist	2015	6	5	4
10.1634/theoncologist.2014-0243	Clinicopathological and Immunohistochemical Characteristics in Male Breast Cancer: A Retrospective Case Series	G. Masci, M. Caruso, F. Caruso, P. Salvini, C. Carnaghi, L. Giordano, V. Miserocchi, A. Losurdo, M. Zuradelli, R. Torrisi, L. Di Tommaso, C. Tinterri, A. Testori, C. A. Garcia-Etienne, W. Gatzemeier, A. Santoro	Oncologist	2015	5	5	5
10.1634/theoncologist.2014-0358	Advances in Anticancer Immunotoxin Therapy	C. Alewine, R. Hassan, I. Pastan	Oncologist	2015	5	5	4
10.1634/theoncologist.2014-0391	TERT Promoter Mutations and TERT mRNA but Not FGFR3 Mutations Are Urinary Biomarkers in Han Chinese Patients With Urothelial Bladder Cancer	K. Wang, T. Liu, C. Liu, Y. Meng, X. Yuan, L. Liu, N. Ge, J. Liu, C. Wang, H. Ren, K. Yan, S. Hu, Z. Xu, Y. Fan, D. Xu	Oncologist	2015	5	5	3
10.1634/theoncologist.2014-0412	Molecular Phenotype of Breast Cancer According to Time Since Last Pregnancy in a Large Cohort of Young Women	L. C. Collins, S. Gelber, J. D. Marotti, S. White, K. Ruddy, E. F. Brachtel, L. Schapira, S. E. Come, V. F. Borges, P. Schedin, E. Warner, T. Wensley, R. M. Tamimi, E. P. Winer, A. H. Partridge	Oncologist	2015	5	5	3
10.1634/theoncologist.2014-0429	Adjusting for the Confounding Effects of Treatment Switching--The BREAK-3 Trial: Dabrafenib Versus Dacarbazine	N. R. Latimer, K. R. Abrams, M. M. Amonkar, C. Stapelkamp, R. S. Swann	Oncologist	2015	5	5	3
10.1634/theoncologist.2014-0442	Molecular Targets in Biliary Carcinogenesis and Implications for Therapy	T. Oyasiji, J. Zhang, B. Kuvshinoff, R. Iyer, S. N. Hochwald	Oncologist	2015	5	5	5
10.1634/theoncologist.2014-0453	Poor Awareness of Risk Factors for Cancer in Irish Adults: Results of a Large Survey and Review of the Literature	A. M. Ryan, S. Cushen, H. Schellekens, E. N. Bhuachalla, L. Burns, U. Kenny, D. G. Power	Oncologist	2015	7	5	5
10.1634/theoncologist.2015-0145	Algorithms in the First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma--Analysis Using Diagnostic Nodes	C. Rothermundt, A. Bailey, L. Cerbone, T. Eisen, B. Escudier, S. Gillessen, V. Grunwald, J. Larkin, D. McDermott, J. Oldenburg, C. Porta, B. Rini, M. Schmidinger, C. Sternberg, P. M. Putora	Oncologist	2015	5	5	4
10.1634/theoncologist.2015-0149	The Therapeutic Challenge of Targeting HER2 in Endometrial Cancer	E. J. Diver, R. Foster, B. R. Rueda, W. B. Growdon	Oncologist	2015	5	5	2
10.1634/theoncologist.2015-0198	Challenges in the Diagnosis and Management of Well-Differentiated Neuroendocrine Tumors of the Lung (Typical and Atypical Carcinoid): Current Status and Future Considerations	E. M. Wolin	Oncologist	2015	5	5	3
10.1634/theoncologist.2015-0210	Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma	L. Goyal, A. Govindan, R. A. Sheth, V. Nardi, L. S. Blaszkowsky, J. E. Faris, J. W. Clark, D. P. Ryan, E. L. Kwak, J. N. Allen, J. E. Murphy, S. K. Saha, T. S. Hong, J. Y. Wo, C. R. Ferrone, K. K. Tanabe, D. Q. Chong, V. Deshpande, D. R. Borger, A. J. Iafrate, N. Bardeesy, H. Zheng, A. X. Zhu	Oncologist	2015	5	5	2
10.1634/theoncologist.2013-0322	Bevacizumab in Treatment of High-Risk Ovarian Cancer--A Cost-Effectiveness Analysis	J. K. Chan, T. J. Herzog, L. Hu, B. J. Monk, T. Kiet, K. Blansit, D. S. Kapp, X. Yu	Oncologist	2014	6	4	2
10.1634/theoncologist.2014-0044	Platinum-Induced Neurotoxicity and Preventive Strategies: Past, Present, and Future	A. Avan, T. J. Postma, C. Ceresa, A. Avan, G. Cavaletti, E. Giovannetti, G. J. Peters	Oncologist	2015	4	4	3
10.1634/theoncologist.2014-0086	Phase II and Pharmacodynamic Study of Autophagy Inhibition Using Hydroxychloroquine in Patients With Metastatic Pancreatic Adenocarcinoma	B. M. Wolpin, D. A. Rubinson, X. Wang, J. A. Chan, J. M. Cleary, P. C. Enzinger, C. S. Fuchs, N. J. McCleary, J. A. Meyerhardt, K. Ng, D. Schrag, A. L. Sikora, B. A. Spicer, L. Killion, H. Mamon, A. C. Kimmelman	Oncologist	2014	4	4	3
10.1634/theoncologist.2014-0144	A Meta-Analysis on the Impact of Platinum-Based Adjuvant Treatment on the Outcome of Borderline Ovarian Tumors With Invasive Implants	I. Vasconcelos, J. Olschewski, I. Braicu, J. Sehouli	Oncologist	2015	4	4	4
10.1634/theoncologist.2014-0149	Posterior Reversible Encephalopathy Syndrome in Patients With Cancer	S. Singer, C. Grommes, A. S. Reiner, M. K. Rosenblum, L. M. DeAngelis	Oncologist	2015	4	4	4
10.1634/theoncologist.2014-0206	M1 Stage Subdivision and Treatment Outcome of Patients With Bone-Only Metastasis of Nasopharyngeal Carcinoma	L. Shen, J. Dong, S. Li, Y. Wang, A. Dong, W. Shu, M. Wu, C. Pan, Y. Xia, P. Wu	Oncologist	2015	5	4	3
10.1634/theoncologist.2014-0227	Effectiveness of Trastuzumab in First-Line HER2+ Metastatic Breast Cancer After Failure in Adjuvant Setting: A Controlled Cohort Study	E. Negri, A. Zambelli, M. Franchi, M. Rossi, M. Bonifazi, G. Corrao, L. Moja, C. Zocchetti, C. La Vecchia	Oncologist	2014	4	4	2
10.1634/theoncologist.2014-0313	Differentiated Thyroid Cancer: Focus on Emerging Treatments for Radioactive Iodine-Refractory Patients	J. J. Gruber, A. D. Colevas	Oncologist	2015	4	4	4
10.1634/theoncologist.2014-0364	BRCA1 and BRCA2 Mutations in Ethnic Lebanese Arab Women With High Hereditary Risk Breast Cancer	N. S. El Saghir, N. K. Zgheib, H. A. Assi, K. E. Khoury, Y. Bidet, S. M. Jaber, R. N. Charara, R. A. Farhat, F. Y. Kreidieh, S. Decousus, P. Romero, G. M. Nemer, Z. Salem, A. Shamseddine, A. Tfayli, J. Abbas, F. Jamali, M. Seoud, D. K. Armstrong, Y.-J. Bignon, N. Uhrhammer	Oncologist	2015	4	4	4
10.1634/theoncologist.2014-0377	Locally Advanced Gastroesophageal Junction Tumor: A Treatment Dilemma	N. Ashraf, S. Hoffe, R. Kim	Oncologist	2015	4	4	4
10.1634/theoncologist.2014-0425	BRCAPRO 6.0 Model Validation in Male Patients Presenting for BRCA Testing	Z. I. Mitri, M. Jackson, C. Garby, J. Song, S. H. Giordano, G. N. Hortobagyi, C. N. Singletary, S. S. Hashmi, B. K. Arun, J. K. Litton	Oncologist	2015	4	4	3
10.1634/theoncologist.2015-0057	Targeting the WNT Signaling Pathway in Cancer Therapeutics	D. Tai, K. Wells, J. Arcaroli, C. Vanderbilt, D. L. Aisner, W. A. Messersmith, C. H. Lieu	Oncologist	2015	4	4	4
10.1634/theoncologist.2015-0064	Therapeutic Effects of Repurposed Therapies in Non-Small Cell Lung Cancer: What Is Old Is New Again	A. Saxena, D. Becker, I. Preeshagul, K. Lee, E. Katz, B. Levy	Oncologist	2015	6	4	4
10.1634/theoncologist.2013-0180	Profiling Cancer Gene Mutations in Clinical Formalin-Fixed, Paraffin-Embedded Colorectal Tumor Specimens Using Targeted Next-Generation Sequencing	L. Zhang, L. Chen, S. Sah, G. J. Latham, R. Patel, Q. Song, H. Koeppen, R. Tam, E. Schleifman, H. Mashhedi, S. Chalasani, L. Fu, T. Sumiyoshi, R. Raja, W. Forrest, G. M. Hampton, M. R. Lackner, P. Hegde, S. Jia	Oncologist	2014	4	3	2
10.1634/theoncologist.2013-0282	Eribulin Monotherapy in Patients Aged 70 Years and Older With Metastatic Breast Cancer	H. Muss, J. Cortes, L. T. Vahdat, F. Cardoso, C. Twelves, J. Wanders, C. E. Dutcus, J. Yang, S. Seegobin, J. O'Shaughnessy	Oncologist	2014	3	3	2
10.1634/theoncologist.2013-0359	Use of Conjoint Analysis to Assess Breast Cancer Patient Preferences for Chemotherapy Side Effects	K. Beusterien, J. Grinspan, I. Kuchuk, S. Mazzarello, S. Dent, S. Gertler, N. Bouganim, L. Vandermeer, M. Clemons	Oncologist	2014	3	3	3
10.1634/theoncologist.2013-0417	Isocitrate Dehydrogenase 1 (IDH1) Mutation in Breast Adenocarcinoma Is Associated With Elevated Levels of Serum and Urine 2-Hydroxyglutarate	A. T. Fathi, H. Sadrzadeh, A. H. Comander, M. J. Higgins, A. Bardia, A. Perry, M. Burke, R. Silver, C. R. Matulis, K. S. Straley, K. E. Yen, S. Agresta, H. Kim, D. P. Schenkein, D. R. Borger	Oncologist	2014	4	3	2
10.1634/theoncologist.2013-0427	Discordance in Hormone Receptor Status Among Primary, Metastatic, and Second Primary Breast Cancers: Biological Difference or Misclassification?	D. Sighoko, J. Liu, N. Hou, P. Gustafson, D. Huo	Oncologist	2014	4	3	1
10.1634/theoncologist.2013-0457	Clinical Signs of Impending Death in Cancer Patients	D. Hui, R. dos Santos, G. Chisholm, S. Bansal, T. B. Silva, K. Kilgore, C. S. Crovador, X. Yu, M. D. Swartz, P. E. Perez-Cruz, R. d. A. Leite, M. S. d. A. Nascimento, S. Reddy, F. Seriaco, S. Yennu, C. E. Paiva, R. Dev, S. Hall, J. Fajardo, E. Bruera	Oncologist	2014	3	3	3
10.1634/theoncologist.2014-0031	What Keeps Oncologists From Addressing Palliative Care Early on With Incurable Cancer Patients? An Active Stance Seems Key	T. A. Pfeil, K. Laryionava, S. Reiter-Theil, W. Hiddemann, E. C. Winkler	Oncologist	2014	4	3	2
10.1634/theoncologist.2014-0120	Clinical Benefits of Above-Standard Dose of Octreotide LAR in Patients With Neuroendocrine Tumors for Control of Carcinoid Syndrome Symptoms: A Multicenter Retrospective Chart Review Study	J. R. Strosberg, A. B. Benson, L. Huynh, M. S. Duh, J. Goldman, V. Sahai, A. W. Rademaker, M. H. Kulke	Oncologist	2014	3	3	3
10.1634/theoncologist.2014-0170	Management of Elderly Patients With Gliomas	J. Gallego Perez-Larraya, J.-Y. Delattre	Oncologist	2014	3	3	3
10.1634/theoncologist.2014-0178	6-Thioguanine: A Drug With Unrealized Potential for Cancer Therapy	P. N. Munshi, M. Lubin, J. R. Bertino	Oncologist	2014	3	3	3
10.1634/theoncologist.2014-0187	Chemotherapy Dose Adjustment for Obese Patients Undergoing Hematopoietic Stem Cell Transplantation: A Survey on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation	N. Shem-Tov, M. Labopin, L. Moukhtari, F. Ciceri, J. Esteve, S. Giebel, N.-C. Gorin, C. Schmid, A. Shimoni, A. Nagler, M. Mohty	Oncologist	2014	4	3	2
10.1634/theoncologist.2014-0276	How Well Do Medical Oncologists Manage Chronic Cancer Pain? A National Survey	B. Breuer, V. T. Chang, J. H. Von Roenn, C. von Gunten, A. I. Neugut, R. Kaplan, S. Wallenstein, R. K. Portenoy	Oncologist	2015	4	3	2
10.1634/theoncologist.2014-0285	The Role of Smoking Status on the Progression-Free Survival of Non-Small Cell Lung Cancer Patients Harboring Activating Epidermal Growth Factor Receptor (EGFR) Mutations Receiving First-Line EGFR Tyrosine Kinase Inhibitor Versus Platinum Doublet Chemotherapy: A Meta-Analysis of Prospective Randomized Trials	Y. Hasegawa, M. Ando, M. Maemondo, S. Yamamoto, S.-i. Isa, H. Saka, A. Kubo, T. Kawaguchi, M. Takada, R. Rosell, T. Kurata, S.-H. I. Ou	Oncologist	2015	4	3	2
10.1634/theoncologist.2014-0330	Practical Management of Bevacizumab-Related Toxicities in Glioblastoma	A. A. Brandes, M. Bartolotti, A. Tosoni, R. Poggi, E. Franceschi	Oncologist	2015	3	3	2
10.1634/theoncologist.2014-0420	Brentuximab Vedotin in Patients With Hodgkin Lymphoma and a Failed Allogeneic Stem Cell Transplantation: Results From a Named Patient Program at Four Italian Centers	C. Carlo-Stella, F. Ricci, S. Dalto, R. Mazza, M. Malagola, F. Patriarca, S. Viviani, D. Russo, L. Giordano, L. Castagna, P. Corradini, A. Santoro	Oncologist	2015	3	3	2
10.1634/theoncologist.2015-0028	Considering Efficacy and Cost, Where Does Ramucirumab Fit in the Management of Metastatic Colorectal Cancer?	D. A. Goldstein, B. F. El-Rayes	Oncologist	2015	3	3	3
10.1634/theoncologist.2015-0038	Chemotherapy Alone for Patients With Stage II/III Rectal Cancer Undergoing Radical Surgery	S. M. AlGizawy, H. H. Essa, B. M. Ahmed	Oncologist	2015	3	3	2
10.1634/theoncologist.2015-0058	Nutritional Status, Body Surface, and Low Lean Body Mass/Body Mass Index Are Related to Dose Reduction and Severe Gastrointestinal Toxicity Induced by Afatinib in Patients With Non-Small Cell Lung Cancer	O. Arrieta, M. De la Torre-Vallejo, D. Lopez-Macias, D. Orta, J. Turcott, E.-O. Macedo-Perez, K. Sanchez-Lara, L.-A. Ramirez-Tirado, V. E. Baracos	Oncologist	2015	3	3	2
10.1634/theoncologist.2015-0065	The Prevalence and Impact of Hyperglycemia and Hyperlipidemia in Patients With Advanced Cancer Receiving Combination Treatment With the Mammalian Target of Rapamycin Inhibitor Temsirolimus and Insulin Growth Factor-Receptor Antibody Cixutumumab	N. L. Busaidy, P. LoRusso, K. Lawhorn, K. R. Hess, M. A. Habra, S. Fu, D. S. Hong, H. X. Chen, L. A. Doyle, R. Kurzrock, A. Naing	Oncologist	2015	3	3	2
10.1634/theoncologist.2015-0123	Next-Generation Sequencing and Immunohistochemistry as Future Gold Standard of ALK Testing in Lung Cancer?	A. Uguen, M. Talagas, P. Marcorelles, P. Gueguen, S. Costa, S. Andrieu-Key, M. De Braekeleer	Oncologist	2015	3	3	2
10.1634/theoncologist.2015-0180	Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41)	A. E. Jackson, M. Mian, C. Kalpadakis, G. A. Pangalis, A. Stathis, E. Porro, A. Conconi, S. Cortelazzo, G. Gaidano, A. Lopez, None Guillermo, P. W. Johnson, M. Martelli, G. Martinelli, C. Thieblemont, E. D. McPhail, C. Copie-Bergman, S. A. Pileri, A. Jack, E. Campo, L. Mazzucchelli, K. Ristow, T. M. Habermann, F. Cavalli, G. S. Nowakowski, E. Zucca	Oncologist	2015	3	3	3
10.1634/theoncologist.2015-0202	Phase I/II Study of Weekly Oraxol for the Second-Line Treatment of Patients With Metastatic or Recurrent Gastric Cancer	K.-W. Lee, K. H. Lee, D. Y. Zang, Y. I. Park, D. B. Shin, J. W. Kim, S.-A. Im, S. A. Koh, K.-S. Yu, J.-Y. Cho, J.-A. Jung, Y.-J. Bang	Oncologist	2015	3	3	1
10.1634/theoncologist.2013-0379	Postchemotherapy Surgery for Germ Cell Tumors--What Have We Learned in 35 Years?	S. B. Riggs, E. F. Burgess, K. E. Gaston, C. A. Merwarth, D. Raghavan	Oncologist	2014	3	2	1
10.1634/theoncologist.2013-0407	STAT3 Inhibitors: Finding a Home in Lymphoma and Leukemia	J. Munoz, N. Dhillon, F. Janku, S. S. Watowich, D. S. Hong	Oncologist	2014	6	2	2
10.1634/theoncologist.2013-0419	Phase II Study of Afatinib as Third-Line Treatment for Patients in Korea With Stage IIIB/IV Non-Small Cell Lung Cancer Harboring Wild-Type EGFR	M.-J. Ahn, S.-W. Kim, B.-C. Cho, J. S. Ahn, D. H. Lee, J.-M. Sun, D. Massey, M. Kim, Y. Shi, K. Park	Oncologist	2014	2	2	2
10.1634/theoncologist.2013-0432	The Clinical Approach Toward Giant Cell Tumor of Bone	L. van der Heijden, P. D. S. Dijkstra, M. A. J. van de Sande, J. R. Kroep, R. A. Nout, C. S. P. van Rijswijk, J. V. M. G. Bovee, P. C. W. Hogendoorn, H. Gelderblom	Oncologist	2014	2	2	2
10.1634/theoncologist.2013-0437	Implications of Functional Proteomics in Breast Cancer	Y. K. Chae, A. M. Gonzalez-Angulo	Oncologist	2014	2	2	2
10.1634/theoncologist.2013-0472	Bone-Targeting Radiopharmaceuticals for the Treatment of Bone-Metastatic Castration-Resistant Prostate Cancer: Exploring the Implications of New Data	C. J. Ryan, P. J. Saylor, J. J. Everly, O. Sartor	Oncologist	2014	2	2	2
10.1634/theoncologist.2014-0011	Enabling a Genetically Informed Approach to Cancer Medicine: A Retrospective Evaluation of the Impact of Comprehensive Tumor Profiling Using a Targeted Next-Generation Sequencing Panel	D. B. Johnson, K. H. Dahlman, J. Knol, J. Gilbert, I. Puzanov, J. Means-Powell, J. M. Balko, C. M. Lovly, B. A. Murphy, L. W. Goff, V. G. Abramson, M. A. Crispens, I. A. Mayer, J. D. Berlin, L. Horn, V. L. Keedy, N. M. Reddy, C. L. Arteaga, J. A. Sosman, W. Pao	Oncologist	2014	2	2	2
10.1634/theoncologist.2014-0028	An Open-Label Phase II Study Evaluating the Safety and Efficacy of Ramucirumab Combined With mFOLFOX-6 as First-Line Therapy for Metastatic Colorectal Cancer	R. Garcia-Carbonero, F. Rivera, J. Maurel, J.-P. M. Ayoub, M. J. Moore, A. Cervantes, T. R. Asmis, J. D. Schwartz, F. Nasroulah, S. Ballal, J. Tabernero	Oncologist	2014	2	2	2
10.1634/theoncologist.2014-0033	Safety Profile of Pertuzumab With Trastuzumab and Docetaxel in Patients From Asia With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Results From the Phase III Trial CLEOPATRA	S. M. Swain, Y.-H. Im, S.-A. Im, V. Chan, D. Miles, A. Knott, E. Clark, G. Ross, J. Baselga	Oncologist	2014	2	2	2
10.1634/theoncologist.2014-0037erratum	Real-World Study of Everolimus in Advanced Progressive Neuroendocrine Tumors	F. Panzuto, M. Rinzivillo, N. Fazio, F. de Braud, G. Luppi, M. C. Zatelli, F. Lugli, P. Tomassetti, F. Riccardi, C. Nuzzo, M. P. Brizzi, A. Faggiano, A. Zaniboni, E. Nobili, D. Pastorelli, S. Cascinu, M. Merlano, S. Chiara, L. Antonuzzo, C. Funaioli, F. Spada, S. Pusceddu, A. Fontana, M. R. Ambrosio, A. Cassano, D. Campana, G. Carteni, M. Appetecchia, A. Berruti, A. Colao, M. Falconi, G. Delle Fave	Oncologist	2015	2	2	2
10.1634/theoncologist.2014-0058	Quality of Life in the Trastuzumab for Gastric Cancer Trial	T. Satoh, Y.-J. Bang, E. A. Gotovkin, Y. Hamamoto, Y.-K. Kang, V. M. Moiseyenko, A. Ohtsu, E. Van Cutsem, N. Al-Sakaff, A. Urspruch, J. Hill, H. A. Weber, H.-C. Chung, None None	Oncologist	2014	2	2	1
10.1634/theoncologist.2014-0089	U.S. Food and Drug Administration Approval Summary: Erlotinib for the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 19 Deletions or Exon 21 (L858R) Substitution Mutations	S. Khozin, G. M. Blumenthal, X. Jiang, K. He, K. Boyd, A. Murgo, R. Justice, P. Keegan, R. Pazdur	Oncologist	2014	3	2	2
10.1634/theoncologist.2014-0202	Age-Related Changes in Nanoparticle Albumin-Bound Paclitaxel Pharmacokinetics and Pharmacodynamics: Influence of Chronological Versus Functional Age	A. Hurria, M. S. Blanchard, T. W. Synold, J. Mortimer, C. T. Chung, T. Luu, V. Katheria, A. J. Rotter, C. Wong, A. Choi, T. Feng, R. Ramani, C. M. Doan, J. Brown, G. Somlo	Oncologist	2014	2	2	2
10.1634/theoncologist.2014-0218	Cost Structure and Clinical Outcome of a Stem Cell Transplantation Program in a Developing Country: The Experience in Northeast Mexico	J. C. Jaime-Perez, A. C. Heredia-Salazar, O. G. Cantu-Rodriguez, H. Gutierrez-Aguirre, C. D. Villarreal-Villarreal, C. Mancias-Guerra, J. L. Herrera-Garza, D. Gomez-Almaguer	Oncologist	2015	3	2	1
10.1634/theoncologist.2014-0295	Imaging Radiation Doses and Associated Risks and Benefits in Subjects Participating in Breast Cancer Clinical Trials	R. Fresco, G. Spera, C. Meyer, P. Cabral, J. R. Mackey	Oncologist	2015	2	2	1
10.1634/theoncologist.2014-0299	Diastolic Dysfunction Occurs Early in HER2-Positive Breast Cancer Patients Treated Concurrently With Radiation Therapy and Trastuzumab	L. Cao, G. Cai, C. Chang, A.-Y. Miao, X.-L. Yu, Z.-Z. Yang, J.-L. Ma, Q. Zhang, J. Wu, X.-M. Guo, J.-Y. Chen	Oncologist	2015	2	2	2
10.1634/theoncologist.2014-0311	A Nationwide Population-Based Retrospective Cohort Study of the Risk of Uterine, Ovarian and Breast Cancer in Women With Polycystic Ovary Syndrome	C.-C. Shen, A. C. Yang, J.-H. Hung, L.-Y. Hu, S.-J. Tsai	Oncologist	2014	3	2	2
10.1634/theoncologist.2014-0382	External Quality Assessment Unravels Interlaboratory Differences in Quality of RAS Testing for Anti-EGFR Therapy in Colorectal Cancer	V. Tack, M. J. L. Ligtenberg, L. Tembuyser, N. Normanno, S. Vander Borght, J. Han van Krieken, E. M. C. Dequeker	Oncologist	2015	2	2	1
10.1634/theoncologist.2014-0394	Prognostic Factors of Survival in a Randomized Phase III Trial (MPACT) of Weekly nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer	J. Tabernero, E. G. Chiorean, J. R. Infante, S. R. Hingorani, V. Ganju, C. Weekes, W. Scheithauer, R. K. Ramanathan, D. Goldstein, D. N. Penenberg, A. Romano, S. Ferrara, D. D. Von Hoff	Oncologist	2015	2	2	2
10.1634/theoncologist.2014-0432	Comparative Effectiveness of Mitoxantrone Plus Prednisone Versus Prednisone Alone in Metastatic Castrate-Resistant Prostate Cancer After Docetaxel Failure	A. K. Green, R. W. Corty, W. A. Wood, M. Meeneghan, K. E. Reeder-Hayes, E. Basch, M. I. Milowsky, S. B. Dusetzina	Oncologist	2015	2	2	2
10.1634/theoncologist.2014-0467	Prospective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer: Results From the SWITCH Study	J. Gligorov, X. B. Pivot, W. Jacot, H. L. Naman, D. Spaeth, J.-L. Misset, R. Largillier, J.-L. Sautiere, A. de Roquancourt, C. Pomel, P. Rouanet, R. Rouzier, F. M. Penault-Llorca, None None	Oncologist	2015	2	2	2
10.1634/theoncologist.2014-0468	Clinical Activity of Ipilimumab in Acral Melanoma: A Retrospective Review	D. B. Johnson, C. Peng, R. G. Abramson, F. Ye, S. Zhao, J. D. Wolchok, J. A. Sosman, R. D. Carvajal, C. E. Ariyan	Oncologist	2015	2	2	2
10.1634/theoncologist.2014-0500	Diastolic Dysfunction Following Anthracycline-Based Chemotherapy in Breast Cancer Patients: Incidence and Predictors	J. M. Serrano, I. Gonzalez, S. Del Castillo, J. Muniz, L. J. Morales, F. Moreno, R. Jimenez, C. Cristobal, C. Graupner, P. Talavera, A. Curcio, P. Martinez, J. A. Guerra, J. J. Alonso	Oncologist	2015	2	2	2
10.1634/theoncologist.2015-0007	Symptoms and Symptom Attribution Among Women on Endocrine Therapy for Breast Cancer	S. M. Rosenberg, A. L. Stanton, K. J. Petrie, A. H. Partridge	Oncologist	2015	2	2	1
10.1634/theoncologist.2015-0008	Choice of Starting Dose for Biopharmaceuticals in First-in-Human Phase I Cancer Clinical Trials	A. R. Hansen, N. Cook, M. S. Ricci, A. Razak, C. Le Tourneau, K. McKeever, L. Roskos, R. Dixit, L. L. Siu, M. J. Hinrichs	Oncologist	2015	2	2	1
10.1634/theoncologist.2015-0015	Surprise Questions for Survival Prediction in Patients With Advanced Cancer: A Multicenter Prospective Cohort Study	J. Hamano, T. Morita, S. Inoue, M. Ikenaga, Y. Matsumoto, R. Sekine, T. Yamaguchi, T. Hirohashi, T. Tajima, R. Tatara, H. Watanabe, H. Otani, C. Takigawa, Y. Matsuda, H. Nagaoka, M. Mori, N. Yamamoto, M. Shimizu, T. Sasara, H. Kinoshita	Oncologist	2015	2	2	2
10.1634/theoncologist.2015-0036	Imaging in Lymphoma: The Key Role of Fluorodeoxyglucose-Positron Emission Tomography	M. Meignan, M. Hutchings, L. H. Schwartz	Oncologist	2015	2	2	2
10.1634/theoncologist.2015-0094	Fibrogenesis in Primary Myelofibrosis: Diagnostic, Clinical, and Therapeutic Implications	A. Nazha, J. D. Khoury, R. K. Rampal, N. Daver	Oncologist	2015	2	2	2
10.1634/theoncologist.2015-0097	Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical Center	L. J. Tafe, I. P. Gorlov, F. B. de Abreu, J. A. Lefferts, X. Liu, J. R. Pettus, J. D. Marotti, K. J. Bloch, V. A. Memoli, A. A. Suriawinata, K. H. Dragnev, C. E. Fadul, G. N. Schwartz, C. R. Morgan, B. M. Holderness, J. D. Peterson, G. J. Tsongalis, T. W. Miller, M. D. Chamberlin	Oncologist	2015	2	2	2
10.1634/theoncologist.2015-0125	Continuous Trastuzumab Therapy in Breast Cancer Patients With Asymptomatic Left Ventricular Dysfunction	A. F. Yu, N. U. Yadav, A. A. Eaton, B. Y. Lung, H. T. Thaler, J. E. Liu, C. A. Hudis, C. T. Dang, R. M. Steingart	Oncologist	2015	2	2	2
